'Botox index' points to declining cosmeceuticals

Allergan's sales woes are a tipoff to declining sales of cosmetic pharmaceuticals in general: Despite predictions that Botox would be recession-proof, the wrinkle fighter lost 3 percent of its sales in the fourth quarter to come in at $329 million, and the company's dermal fillers saw revenues sink by 8.8 percent to $56 million. Experts predict the trend will apply at other companies, too. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.